The Importance of Gestational Age as a Prognostic Factor on Norwood Stage 1 Outcome

Ergin Arslanoğlu¹, Kenan Abdurrahman Kara¹, Ali Can Hatemi², Berra Zümrüt Tan¹, Ömer Faruk Şavluk³, Fatma Ukil Işıldak³, Eylem Tunçer¹, Nihat Çine¹, Hakan Ceyran¹

¹ Department of Pediatric Cardiovascular Surgery, Kartal Koşuyolu High Specialization Training and Research Hospital, Istanbul, Turkey

² Department of Pediatric Cardiovascular Surgery, Başakşehir Çam ve Sakura City Hospital, Istanbul, Turkey

³ Department of Anaesthesiology and Reanimation, Kartal Koşuyolu High Specialization Training and Research Hospital, Istanbul, Turkey

ABSTRACT

Introduction: The Norwood operation performed for hypoplastic left heart syndrome in the neonatal period remains to be a high-risk and difficult surgical procedure. It is known that preterm birth often accompanied by low birth weight is associated with high mortality and morbidity in these patients.

Patients and Methods: The study included 54 patients who underwent the Norwood procedure in our clinic in the period between December 2012 and December 2019. Patient data were evaluated retrospectively; including gestational week, age, body weight, total bypass time, aortic cross-clamp time, extubation time, the length of stay in the intensive care unit, the length of hospital stay, and the preoperative and postoperative levels of urea, creatinine, alanine aminotransferase, aspartate aminotransferase, and platelet counts.

Results: The body weight of the patients ranged from 2350 to 4500 grams with an average of 3296.3 ± 486.7 grams. The age of the patients at the time of operation ranged from 1 to 374 days with an average of 30.31 ± 70.51 days. The comparison of patients by term pregnancies resulted in no statistically significant differences but the comparison by gestational weeks revealed a statistically significant result.

Conclusion: Preoperative risk factors affect prognosis more than the surgical technique and the treatment approach in patients with a functional single ventricle. When the gestational week was evaluated as a preoperative risk factor for its effects on the postoperative prognosis of stage 1 Norwood operation in our study, it was found that mortality decreased significantly after the 38.8th gestational week (272 gestational days).

Key Words: Gestational age; norwood; pediatric heart surgery.

Gestasyonel Haftanın Norwood Stage 1 Sonuçlarına Prognostik Etkisi

ÖΖ

Giriş: Hipoplastik sol kalp sendromu olan hastalarda yenidoğan döneminde yapılan norwood prosedürü halen riskli ve zor bir cerrahi işlemdir. Bu hastalarda preterm doğum ve preterm doğuma sıklıkla eşlik eden düşük doğum ağırlığının mortalite ve morbiditeyi artırdığı bilinmektedir.

Hastalar ve Yöntem: Çalışmaya Aralık 2012-Aralık 2019 tarihleri arasında kliniğimizde Norwood prosedürü uygulanan 54 hasta dahil edilmiştir. Hastaların gestasyonel hafta, yaş, kilo, total baypas süresi, aortik kross klemp süresi, ekstübasyon zamanı, yoğun bakım kalış ve servis yatış süreleri, preoperatif, postoperatif üre, kreatinin, alanın aminotransferaz, aspartat aminotransferaz, trombosit değerleri retrospektif olarak değerlendirilmiştir.

Bulgular: Hastaların kilo değeri 2350 ile 4500 gram arasında değişmekte olup ortalama 3296.3 \pm 486.7 gram bulunmuştur. Hastaların operasyon sırasındaki yaşı 1 ile 374 gün arasında değişmekte olup ortalama 30.31 \pm 70.51 gün bulunmuştur. Hastalar termlere göre kıyaslandıklarında istatistiksel olarak anlamlı sonuç bulunmamış, fakat gestasyonel haftaya göre kıyaslandıklarında istatistiksel olarak anlamlı sonuç elde edilmiştir.

Sonuç: Fonksiyonel tek ventriküle sahip hastalarda preoperatif risk faktörleri prognoza cerrahi teknik ve tedavi yaklaşımından daha fazla etkilir. Çalışmamızda preoperatif risk faktörlerinden biri olan gestasyonel hafta ile norwood stage 1 operasyonun postoperatif prognozu açısından karşılaştırıldığında 38,8. gestasyonel haftadan (272 gestasyonel gün) sonra mortalite anlamlı olarak düşmüştür.

Anahtar Kelimeler: Gestasyonel hafta; norwood; pediatrik kalp cerrahisi.

INTRODUCTION

Hypoplastic left heart syndrome (HLHS), defined as mitral atresia or stenosis and left ventricular hypoplasia with aortic atresia or stenosis, is a disease that requires surgical



Cite this article as: Arslanoğlu E, Kara KA, Hatemi AC, Tan BZ, Şavluk ÖF, Ukil Işıldak F, et al. The importance of gestational age as a prognostic factor on norwood stage 1 outcome. Koşuyolu Heart J 2021;24(Suppl 1):S18-S25.

Correspondence

Ergin Arslanoğlu

E-mail: erginarslanoglu@gmail.com Submitted: 18.05.2021 Accepted: 02.07.2021 Available Online Date: 11.07.2021

© Copyright 2021 by Koşuyolu Heart Journal Available on-line at www.kosuyoluheartjournal.com correction in the neonatal period because such patients cannot survive without surgical interventions. The Norwood procedure has been used in single-ventricle patients since 1983. Despite advances in pediatric cardiac surgery, the Norwood procedure is still a high-risk and difficult surgical procedure⁽¹⁻⁴⁾.

Although the information about the relationship between the gestational week at term and congenital heart diseases is limited, it is known that low birth weight (less than 2500 g) and preterm birth (before 37 weeks of gestation) are risk factors for the occurrence of neurodevelopmental problems and cardiovascular complications after the Norwood operation. Low birth weight; which often accompanies preterm birth in single ventricle patients, increases mortality and morbidity associated with complex cardiac surgery that should be performed shortly after the birth of the infant⁽⁵⁻⁹⁾.

Although the effect of prenatal development of vital organs such as lungs, kidneys, and the brain on the development of preoperative and postoperative complications has not been clarified yet, low gestational week and low birth weight are shown as risk factors in previous studies⁽¹⁰⁻¹⁴⁾.

In our study; we will present the effect of the gestational week on the early postoperative prognosis of patients, who underwent the Norwood stage 1 procedure due to the diagnosis of a single ventricle.

PATIENTS and METHODS

The study included 54 patients; who underwent the Norwood procedure in our hospital in the period between December 2012 and December 2019. Age, weight, operation time, total bypass time, aortic cross-clamping (CC) time, preoperative patent ductus arteriosus (PDA) diameter, extubation time, the length of intensive care unit (ICU) stay, the length of stay in the inpatient unit, and the preoperative and postoperative values of urea, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet counts of patients were evaluated retrospectively.

Conventional median sternotomy and selective bicaval cannulation were performed in all cases. Aortic arch repair procedures were performed under total circulatory arrest (18°C) after deep hypothermia in four patients and through the cannulation of the descending aorta with antegrade cerebral perfusion in the rest of the patients. Myocardial protection was performed by administering a single dose of custodiol cardioplegia solution in all patients.

Although pulmonary shunts were placed between the right ventricle and the pulmonary artery (RV-PA) in the majority of the patients, subclavian-PA shunts were preferred in 14 patients.

In this retrospective cohort study, the NCSS software (Number Cruncher Statistical System, 2007, Kaysville, Utah, USA) was used for statistical analysis. Descriptive statistics (mean, standard deviation, median, frequency, percentage, minimum, and maximum) was used to summarize the data. The distribution of the data was evaluated by the Shapiro-Wilk test. The Kruskal-Wallis test was used for comparisons across three or more groups that did not show a normal distribution of quantitative data and the Mann-Whitney U test was used for comparisons of two groups with quantitative data not conforming to a normal distribution. The Friedman test was used for comparing three or more conditions of non-normally distributed periodic quantitative data and the Wilcoxon test was used to determine the differences. Spearman's correlation test was used to determine relationships across quantitative data. The ROC analysis was used to determine the predictive value of the quantitative data. Statistical significance was evaluated at p < 0.01 and p = 0.05.

The study protocol was approved by the ethics committee. This study was conducted in accordance with the principles of the Declaration of Helsinki (2021/4/457).

RESULTS

The body weight of the patients ranged from 2350 to 4500 grams with an average of 3296.3 ± 486.7 grams. The age of the patients at the time of operation ranged from 1 to 374 days with an average of 30.31 ± 70.51 days. Weeks of gestation varied between 242 and 295 days with an average of $265.61 \pm$ 10.57 days. Changes between preoperative and postoperative ALT levels varied from -686 to 73 U/L with a mean of -22.97 \pm 99.96 U/L. Changes between preoperative and postoperative AST levels varied from -3233 to 2322 U/L with a mean of 22.5 ± 615.79 U/L. Changes between preoperative and postoperative urea levels varied from -25 to 161 mg/dL with a mean of $22.06 \pm$ 30.68 mg/dL. Changes between preoperative and postoperative creatinine levels varied from -0.65 to 3.11 mg/dL with a mean of 0.29 ± 0.64 mg/dL. Changes between preoperative and postoperative platelet counts varied from -474 to 203 103/µL with a mean of $-109.56 \pm 129.95 \ 103/\mu$ L. PDA diameters ranged from 2.3 to 11 mm with an average of 5.75 ± 1.71 mm. Postoperative saturation values ranged from 60% to 96% with an average of $81.8 \pm 6.31\%$. Bypass times ranged from 134 to 405 minutes with an average of 215.98 ± 62.38 minutes. CC times ranged from 40 to 201 minutes with an average of 91 ± 31.75 minutes. Postoperative vasoactive-inotropic scores (VIS) ranged from 11 to 47 with an average of 22.02 ± 7.77 . Drainage volumes on the first postoperative day ranged from 20 to 580 cc with a mean of 165.93 ± 109.09 cc. The length of ICU stay ranged from 1 to 129 days with an average of 31.22 ± 28 days (Table 1).

Gestational age was not statistically significantly different between the patients that were discharged from the hospital and the patients that died (p > 0.05). However, the mean gestational age of the survivors was higher compared to the patients, who died (Table 2).


Table 1. Demographic data	a	
	Mean ± SD	Min-Max (median)
Weight (gram)	3296.3 ± 486.7	2350-4500 (3200)
Patient age at the operation (days)	30.31 ± 70.51	1-374 (9)
Gestational week (days)	265.61 ± 10.57	242-295 (264)
Preop-Postop change in ALT levels (U/L)	-22.97 ± 99.96	-686-73 (-7)
Preop-Postop change in AST levels (U/L)	22.5 ± 615.79	-3233-2322 (-1.5)
Preop-Postop change in urea levels (mg/dL)	22.06 ± 30.68	-25-161 (14.5)
Preop-Postop change in creatinine levels (mg/dL)	0.29 ± 0.64	-0.65-3.11 (0.14)
Preop-Postop change in PLT count (10 ³ /mL)	-109.56 ± 129.95	-474-203 (-100)
Preop PDA diameter (mm)	5.75 ± 1.71	2.3-11 (5.5)
Postop saturation (%)	81.8 ± 6.31	60-96 (82.5)
Total bypass time (min)	215.98 ± 62.38	134-405 (214.5)
CC time (min)	91 ± 31.75	40-201 (84)
Postop VIS score	22.02 ± 7.77	11-47 (20)
1st day drainage (cc)	165.93 ± 109.09	20-580 (140)
Length of stay in the intensive care unit (days)	31.22 ± 28	1-129 (21.5)

Table 1. Demographic data

The cut-off point of 272 days for gestational age was found out to be reliable with 35.3% sensitivity and 86.5% specificity (Table 3, Figure 1).

Of the patients; 18.5% (n= 10) were preterm, 42.6% (n= 23) were early term, 25.9% (n= 14) were term, and 13% (n= 7) were late term (Table 4, Figure 2).

There is a positive and weakly significant correlation between gestational age and postoperative saturation levels (r= 0.276, p< 0.05). No statistically significant correlations of gestational age exist with changes between preoperative and postoperative ALT, AST, urea, and creatinine levels, and platelet counts; PDA diameters, bypass times, CC times, postoperative VIS scores, drained fluid volumes on the first postoperative day, and the length of stay in ICU (p> 0.05) (Table 5).



Diagonal segments are produced by ties. Figure 1. ROC curve of gestational age.

There is a positive and moderately significant correlation between the levels of change between the preoperative and postoperative ALT and AST values (r=0.552, p<0.01). There is not a statistically significant relationship of ALT levels with urea, and creatinine levels; platelet counts, PDA diameters, postoperative saturation levels, bypass times, CC times, postoperative VIS scores, drained fluid volumes on the first postoperative day, and the length of stay in ICU (p>0.05).

The change between the preoperative and postoperative AST levels is not statistically significantly related to any of the following parameters; including the change between the preoperative and postoperative urea and creatinine levels and platelet counts, PDA diameters, postoperative saturation levels, bypass times, CC times, postoperative VIS scores, the volume of the drained fluid on the first postoperative day, and the length of stay in ICU (p > 0.05).

There is a positive and weakly significant correlation between the changes in preoperative and postoperative urea and creatinine levels (r= 0.493, p< 0.01). There is a positive

Table 2. Comparison of gestational v	weeks (davs) between patients that	were discharged from the	hospital and patients that died

		n	Mean ± SD	Min-Max (median)	р
Gestational day	Died	37	264.95 ± 10.83	242-295 (263)	0.595
	Survived	17	267.06 ± 10.15	253-283 (266)	

Table 3. ROC analysis results for cut-off and AUC values					
Parameter	Sensitivity (%)	Specificity (%)	Cut-off point	Area under the curve	
Gestational week	35.3	86.5	272	55	

Table 4. Distribution of patients by term pregnancies			
Term pregnancies	Preterm (< 37 weeks)	10	18.5
	Early term (37-38 weeks)	23	42.6
	Term (39-40 weeks)	14	25.9
	Late term (> 40 weeks)	7	13.0

and weakly significant relationship between the PDA diameter and changes in preoperative and postoperative urea levels (r= 0.306, p< 0.05). There is a negatively and weakly significant correlation between postoperative VIS scores and changes in preoperative and postoperative urea levels (r= -0.304, p< 0.05). There is not a statistically significant relationship of the change between the preoperative and postoperative urea levels with




Table 5. Correlation analysis 2 3 4 5 6 7 8 9 10 11 12 1 13 1 r 1. Gestational Age (Day) р 2. Preop-0.051 r 1 postop change 0.716 in ALT levels р . 3. Preop-0.049 0.552** 1 r postop change 0.726 0.000 in AST levels р 4. Preop-post-0.076 0.055 0.210 1 r op change in 0.586 0.694 0.128 р urea levels . 5. Preop--0.04 0.243 0.493** 0.246 1 r postop change in creatinine 0.073 0.775 0.076 0.000 р levels 6. preop-post--0.174 0 -0.163 -0.166 -0.054 1 r op change in 0.223 0.208 0.240 0.230 0.697 PLT counts р . 0 0.175 0.306* 0.060 1 r -0.056 -0.022 7. Pre-op PDA Diameter 0.687 0.602 0.206 0.024 0.877 0.666 р 0.276* -0.012 0 0.108 0.048 0.008 1.000 -0.017 r 8. Postop saturation 0.043 0.929 0.65 0.438 0.733 0.952 0.904 р -0.263 -0.229 0 -0.046 0.400** 0.095 0.015 0.066 1 r 9. Total Bypass Time 0.635 0.055 0.096 0.13 0.741 0.003 0.492 0.915 р 0.009 -0.204 -0.242 -0.117 0 0.18 0.171 -0.007 0.565** 1 r 10. CC Time 0.947 0.139 0.078 0.399 0.745 0.193 0.216 0.959 0.000 р 0 0.172 0.044 -0.304* -0.215 0 -0.075 -0.096 0.317* 0.26 1 11. Postop VIS r Scores 0.999 0.215 0.754 0.026 0.118 0.711 0.588 0.489 0.019 0.058 р 12. Day 1 -0.132 -0.019 -0.054 0.123 0.129 -0.172 0 0.148 -0.122 -0.068 -0.111 1 r Drainage Fluid 0.892 0.377 0.352 0.225 0.340 0.697 0.213 0.285 0.380 0.625 0.426 Volume р -0.022 -0.016 0.007 0.225 0.146 -0.003 -0.073 0 -0.237 -0.297* -0.278* 0.312* 1.000 13. Intensive r Care Stay 0.877 0.910 0.960 0.102 0.292 0.985 0.602 0.948 0.085 0.029 0.042 0.022 р

Preop ALT Preterm 10 35.3 ± 28.22 4.81 (28.5) Early term 23 49.57 ± 105.66 1.505 (20) Term 14 64.07 ± 88.7 11.310 (35) Late term 7 111.43 ± 256.48 9.693 (16) Preop AST Preterm 10 59.9 ± 42.09 23-164 (47) Early term 23 82.3 ± 148.38 15-719 (43) Term 14 376.36 ± 872.54 13-3278 (48) Late term 7 534.29 ± 1260.02 16-3391 (62) Preop urea Preterm 10 21.3 ± 12.51 10-44 (15.5) Early term 23 24.52 ± 12.46 6-57 (23) Term 14 30.79 ± 14.92 13-68 (29) Late term 7 40 ± 30.87 10-89 (21) Preop reactinine Preterm 10 0.63 ± 0.29 0.24-1.20 (6.5) Term 14 0.82 ± 0.6 0.16 -2.43 (0.76) 1.34 ± 624.53 Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT			n	Mean ± SD	Min-Max (median)	р
Term 14 64.07 ± 88.7 11.310 (35) Late term 7 111.43 ± 256.48 9.693 (16) Preop AST Preterm 10 59.9 ± 42.09 23.164 (47) Early term 23 82.3 ± 148.38 15.719 (43) Term 14 376.36 ± 872.54 13.3278 (48) Preop urea Preterm 10 21.3 ± 12.51 10-44 (15.5) Early term 23 24.52 ± 12.46 6-57 (23) Term 14 30.79 ± 14.92 13.68 (29) Term 14 30.79 ± 14.92 13.68 (29) Preop creatinine Preterm 10 0.63 ± 0.21 0.29-0.93 (0.64) Early term 23 0.65 ± 0.29 0.24 ± 12 (0.65) Term 14 0.82 ± 0.6 0.16 ± 2.43 (0.76) Term 14 0.82 ± 0.6 0.16 ± 2.43 (0.76) Term 14 0.82 ± 0.6 0.64 ± 0.55 Preop PLT Preterm 10 20.65 ± 1.53 0.64 ± 1.65 Early term 23 3.	Preop ALT	Preterm	10	35.3 ± 28.22	4-81 (28.5)	0.345
Late term 7 111.43 ± 256.48 9-693 (16) Preop AST Preterm 10 59.9 ± 42.09 23-164 (47) Early term 23 & & & & & & & & & & & & & & & & & & &		Early term	23	49.57 ± 105.66	1-505 (20)	
Preop AST Preterm 10 59.9 ± 42.09 23-164 (47) Early term 23 82.3 ± 148.38 15-719 (43) Term 14 376.36 ± 872.54 13.3278 (48) Late term 7 534.29 ± 1260.02 16.3391 (62) Preop urea Preferm 10 21.3 ± 12.51 10-44 (15.5) Early term 23 24.52 ± 12.46 6-57 (23) Term 14 30.79 ± 14.92 13-68 (29) Late term 7 40 ± 3.087 10-89 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.29-0.93 (0.64) Early term 23 0.65 ± 0.29 0.24-1.2 (0.65) Term 14 0.82 ± 0.6 0.16-2.43 (0.76) Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT Preterm 10 30.65 ± 90.99 211.488 (284.5) Early term 23 293.26 ± 105.46 52-727 (25) 2727 (25) Term 14 270.71 ± 130.78 133-625 (259) 24.52 (15)		Term	14	64.07 ± 88.7	11-310 (35)	
Farly term 23 82.3 ± 148.38 15.719 (43) Term 14 376.36 ± 872.54 13-3278 (48) Late term 7 534.29 ± 1260.02 16-3391 (62) Preop urea Preterm 10 21.3 ± 12.51 10-44 (15.5) Early term 23 24.52 ± 12.46 6.57 (23) Term 14 30.079 ± 14.92 13.68 (29) Late term 7 40 ± 30.87 10.89 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.20-90 30 (0.64) Early term 23 0.65 ± 0.29 0.24-1.2 (0.65) Term 14 0.82 ± 0.6 0.16 • 2.43 (0.76) Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211-488 (284.3) Early term 23 36.52 ± 77.84 1.336.62 (28) Ierm 14 200.61 ± 15.8 0.64 ± 16.5) Early term 23 36.52 ± 77.84 1.383 (9) Ierm 14 56.14 ±		Late term	7	111.43 ± 256.48	9-693 (16)	
Early term 23 82.3 ± 148.38 15.719 (43) Term 14 376.36 ± 872.54 13-3278 (48) Late term 7 534.29 ± 1260.02 16-3391 (62) Preop urea Preterm 10 21.3 ± 12.51 10-44 (15.5) Early term 23 24.52 ± 12.46 6.57 (23) Term 14 30.079 ± 14.92 13.68 (29) Late term 7 40 ± 30.87 10-89 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.29.03 (0.64) Early term 23 0.65 ± 0.29 0.24.12 (0.65) Term 14 0.82 ± 0.6 0.16-2.43 (0.76) Late term 7 0.94 ± 0.65 0.22.1.78 (0.85) Preop PLT Preterm 10 30.65 ± 0.09 211-488 (28.43) Early term 23 3.652 ± 77.84 1.336.62 (28) Preop PLT Preterm 10 20.65 ± 5.06 18.180.39) Late term 7 216 ± 128.47 1.383 (16) Ferm 14	Preop AST	Preterm	10	59.9 ± 42.09	23-164 (47)	0.413
Term 14 376.36 ± 872.54 13.3278 (48) Late term 7 534.29 ± 126.02 16-3391 (62) Preop urea Preterm 10 21.3 ± 12.51 10.44 (15.5) Early term 23 24.52 ± 12.46 6-57 (23) Term 14 30.79 ± 14.92 13.68 (29) Preop creatinine Preterm 7 40 ± 30.87 10.489 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.290.93 (0.64) Early term 23 0.65 ± 0.29 0.24.12 (0.65) 0.221.178 (0.85) Preop creatinine Ferm 10 308.5 ± 90.99 211.488 (284.5) Early term 23 293.26 ± 165.46 52.727 (259) Term 14 270.71 ± 130.78 133-625 (258) Early term 23 36.52 ± 77.84 1-383 (16) Term 14 260.45 ± 108.93 1-383 (16) Term 14 56.14 ± 108.93 1-383 (16) Term 14 3692 ± 1.784 1-383 (16)	1					
Late term7 534.29 ± 126.02 $16-3391$ (62)Preop ureaPreterm10 21.3 ± 12.51 $10-44$ (15.5)Early term23 24.52 ± 12.46 $6-57$ (23)Term14 30.79 ± 14.92 $13-68$ (29)Late term7 40 ± 30.87 $10-89$ (21)Preop creatininePreterm10 0.63 ± 0.21 $0.29.093$ (0.64)Early term23 0.65 ± 0.29 $0.24 + 1.2$ (0.65)Term14 0.82 ± 0.6 $0.22 + 1.78$ (0.85)Preop PLTPreterm7 0.94 ± 0.65 $0.22 + 1.78$ (0.85)Preop PLTPreterm10 308.5 ± 90.99 $211-488$ (284.5)Early term23 293.26 ± 165.46 $52 - 727$ (259)Term14 270.71 ± 130.78 133.625 (258)Late term7 216 ± 128.47 $57-361$ (230)Postop ALTPreterm10 20.66 ± 14.58 0.645 (16.5)Early term23 23.652 ± 77.84 $1-383$ (16)Term14 51.14 ± 108.93 $1-383$ (16)Term14 56.14 ± 108.93 $1-383$ (16)Term14 309.21 ± 598.2 3.1863 (84)Late term7 217.29 ± 393.43 20.1103 (65)Postop ASTPreterm10 65.6 ± 50.66 18.180 (39)Early term23 233.48 ± 619.7 12.3041 (104)Term14 309.91 ± 22.14 9.67 (55)Late term7 51.71 ± 25.41 26.85 (43) <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
Preop urea Preterm 10 21.3 ± 12.51 10.44 (15.5) Early term 23 24.52 ± 12.46 6.57 (23) Term 14 30.79 ± 14.92 13.68 (29) Late term 7 40 ± 30.87 10.89 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.29.03 (0.64) Early term 23 0.65 ± 0.29 0.24-1.2 (0.65) Term 14 0.82 ± 0.6 0.16 ± 2.43 (0.76) Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211-488 (284.5) Early term 23 246.52 ± 77.84 133.625 (258) Late term 7 216 ± 128.47 57-361 (230) Postop ALT Preterm 10 20.06 ± 14.58 0.6-45 (16.5) Early term 23 36.52 ± 77.84 1-383 (16) Term 14 56.14 ± 108.93 1-383 (9) Late term 7 14.71 ± 9.34 3-25 (19) Postop AST Pret						
Early term 23 24.52 ± 12.46 6.57 (23) Term 14 30.79 ± 14.92 13.68 (29) Late term 7 40 ± 30.87 10.89 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.29-0.93 (0.64) Early term 23 0.65 ± 0.29 0.24-1.2 (0.65) Term 14 0.82 ± 0.6 0.16-2.43 (0.76) Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211.488 (284.5) Preop PLT Preterm 14 270.71 ± 130.78 133.652 (528) Preop PLT Preterm 14 270.71 ± 130.78 133.651 (530) Postop ALT Preterm 10 20.65 ± 14.58 0.6-45 (16.5) Early term 23 365.2 ± 77.84 1-383 (16) Term 14 56.14 ± 108.93 1-383 (9) Late term 7 14.71 ± 9.34 3-25 (19) Postop AST Preterm 10 65.6 ± 56.06 18-180 (39)	Proop Uroo				· · ·	0.194
Term 14 30.79 ± 14.92 13-68 (29) Late term 7 40 ± 30.87 10-89 (21) Preop creatinine Preterm 10 0.63 ± 0.21 0.29-0.93 (0.64) Early term 23 0.65 ± 0.29 0.24 + 1.2 (0.65) Term 14 0.82 ± 0.6 0.16 ± 2.43 (0.76) Late term 7 0.94 ± 0.65 0.22 - 1.78 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211-488 (284.5) Early term 23 293.26 ± 165.46 52.727 (259) Term 14 270.71 ± 130.78 133-625 (258) Late term 7 216 ± 128.47 57-361 (230) Postop ALT Preterm 10 20.06 ± 14.58 0.6-45 (16.5) Early term 23 36.52 ± 77.84 1-383 (16) Term 14 56.14 ± 108.93 1-383 (16) Term 14 56.14 ± 108.93 1-383 (16) Term 10 65.6 ± 50.60 18-180 (39) Late term 7 217.29 ± 393	reop urea					0.194
Late term740 ± 30.87 $10 \cdot 89$ (2)Preop creatininePreterm10 0.63 ± 0.21 $0.29 \cdot 0.93$ (0.64)Early term23 0.65 ± 0.29 $0.24 \cdot 1.2$ (0.65)Term14 0.82 ± 0.6 $0.16 \cdot 2.43$ (0.76)Late term7 0.94 ± 0.65 $0.22 \cdot 1.78$ (0.85)Preop PLTPreterm10 308.5 ± 90.99 $211 \cdot 488$ (284.5)Early term23 293.26 ± 165.46 $52 \cdot 727$ (259)Term14 270.71 ± 130.78 $133 \cdot 625$ (258)Late term7 216 ± 128.47 $57 \cdot 361$ (230)Postop ALTPreterm10 20.06 ± 14.58 $0.6 \cdot 45$ (16.5)Early term23 36.52 ± 77.84 $1 \cdot 383$ (16)Term14 56.14 ± 108.93 $1 \cdot 383$ (9)Late term7 14.71 ± 9.34 $3 \cdot 25$ (19)Postop ASTPreterm10 65.6 ± 56.06 $18 \cdot 180$ (39)Early term23 233.48 ± 619.7 $12 \cdot 3041$ (104)Term14 36921 ± 598.2 $3 \cdot 1863$ (84)Late term7 217.29 ± 393.43 $20 \cdot 1103$ (65)Postop MSTPreterm10 39.9 ± 22.14 $9 \cdot 87$ (36)Early term23 49.96 ± 36.4 $8 \cdot 184$ (39)Term14 54.93 ± 22.13 $26 \cdot 95$ (55)Late term7 51.71 ± 254 $26 \cdot 85$ (43)Postop reatininePreterm10 0.63 ± 0.37 $0.22 \cdot 1.43$ (0.47)Early term23 1 ± 0.77		-				
Preop creatinine Preterm 10 0.63 ± 0.21 0.29-0.93 (0.64) Early term 23 0.65 ± 0.29 0.24-1.2 (0.65) Term 14 0.82 ± 0.6 0.16-2.43 (0.76) Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211-488 (284.5) Early term 23 293.26 ± 165.46 52-727 (259) Term 14 270.71 ± 130.78 133-625 (258) Late term 7 216 ± 128.47 57-361 (230) Postop ALT Preterm 10 20.06 ± 14.58 0.6-45 (16.5) Early term 23 36.52 ± 77.84 1-383 (16) Term 14 56.14 ± 108.93 1-383 (9) Late term 7 14.71 ± 9.34 3-25 (19) Postop AST Preterm 10 65.6 ± 56.06 18-180 (39) Early term 23 233.48 ± 619.7 12-3041 (104) Term 14 369.21 ± 598.2 3-1863 (84) Late term						
Early term 23 0.65 ± 0.29 0.24±.12 (0.65) Term 14 0.82 ± 0.6 0.16±.243 (0.76) Late term 7 0.94 ± 0.65 0.22±.178 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211448 (284.5) Early term 23 293.26 ± 165.46 52.727 (259) Term 14 270.71 ± 130.78 133-652 (288) Late term 7 216 ± 128.47 57.361 (230) Postop ALT Preterm 10 20.06 ± 14.58 0.6-45 (16.5) Early term 23 36.52 ± 77.84 1-383 (9) 1-383 (9) Late term 7 14.71 ± 9.34 3-25 (19) Postop AST Preterm 10 65.6 ± 5.60.6 18-180 (39) Early term 23 233.48 ± 619.7 12-3041 (104) Term 14 369.21 ± 598.2 3-1863 (84) Late term 7 17.29 ± 393.43 20-1103 (65) Postop urea Preterm 10 39.9 ± 22.14 9.87 (36)	Ducen exectivity -				· ·	0.849
Term14 0.82 ± 0.6 $0.16 \cdot 2.43$ (0.76)Late term7 0.94 ± 0.65 $0.22 \cdot 1.78$ (0.85)Preop PLTPreterm10 308.5 ± 90.99 $211 \cdot 488$ (284.5)Early term23 293.26 ± 165.46 52.727 (259)Term14 270.71 ± 130.78 $133 \cdot 625$ (258)Late term7 216 ± 128.47 $57 \cdot 361$ (230)Postop ALTPreterm10 20.06 ± 14.58 $0.6 \cdot 45$ (16.5)Early term23 36.52 ± 77.84 $1 \cdot 383$ (16)Term14 56.14 ± 108.93 $1 \cdot 383$ (9)Late term7 14.71 ± 9.34 $3 \cdot 25$ (19)Postop ASTPreterm10 65.6 ± 56.06 $18 \cdot 180$ (39)Early term23 233.48 ± 619.7 $12 \cdot 3041$ (104)Term14 369.21 ± 598.2 $3 \cdot 1863$ (84)Late term7 217.29 ± 393.43 $20 \cdot 1103$ (65)Postop ureaPreterm10 3.99 ± 22.14 9.87 (36)Postop ureaPreterm10 6.63 ± 0.37 $0.22 \cdot 1.43$ (0.47)Postop creatininePreterm10 6.63 ± 0.37 $0.22 \cdot 1.43$ (0.47)Postop reatininePreterm14 123 ± 0.71 $0.34 \cdot 2.33$ (1.04)Postop CreatininePreterm10 6.63 ± 0.37 $0.22 \cdot 1.43$ (0.47)Postop CreatininePreterm14 123 ± 0.71 $0.34 \cdot 2.33$ (1.04)Postop PLTPreterm10 12.23 ± 54.38 54.216 (1.7)Postop PLTPre	reop creatinine					0.849
Late term 7 0.94 ± 0.65 0.22-1.78 (0.85) Preop PLT Preterm 10 308.5 ± 90.99 211-488 (284.5) Early term 23 293.26 ± 165.46 52-727 (259) Term 14 270.71 ± 130.78 133-625 (258) Late term 7 216 ± 128.47 57-361 (230) Postop ALT Preterm 10 20.06 ± 14.58 0.6-45 (16.5) Early term 23 36.52 ± 77.84 1-383 (16) Term 14 56.14 ± 108.93 1-383 (9) Destop ALT Preterm 10 65.6 ± 56.06 18-180 (39) Destop AST Preterm 10 65.6 ± 56.06 18-180 (39) Destop AST Preterm 14 369.21 ± 598.2 3-1863 (84) Late term 7 217.29 ± 393.43 20-1103 (65) Destop urea Preterm 10 39.9 ± 22.14 9-87 (36) Early term 23 49.96 ± 36.4 8-184 (39) Term 14 54.93 ± 22.13 26-99 (55.5)		Early term	23	0.65 ± 0.29		
Preop PLT Preterm 10 308.5 ± 90.99 211-488 (284.5) Early term 23 293.26 ± 165.46 52.727 (259) Term 14 270.71 ± 130.78 133-625 (258) Late term 7 216 ± 128.47 57-361 (230) Postop ALT Preterm 10 20.06 ± 14.58 0.6-45 (16.5) Early term 23 36.52 ± 77.84 1-383 (16) Term 14 56.14 ± 108.93 1-383 (9) Late term 7 14.71 ± 9.34 3-25 (19) Postop AST Preterm 10 65.6 ± 56.06 18-180 (39) Early term 23 233.48 ± 619.7 12-3041 (104) Term 14 369.21 ± 598.2 3-1863 (84) Late term 7 217.29 ± 393.43 20-1103 (65) Postop urea Preterm 10 39.9 ± 22.14 9-87 (36) Early term 23 49.96 ± 36.4 8-184 (39) Term 14 54.93 ± 22.13 26-59 (55.5) Late term 7		Term				
LEarly term23293.26 ± 165.46 52.727 (25)Term14 270.71 ± 130.78 133.625 (258)Late term7 216 ± 128.47 57.361 (230)Postop ALTPreterm10 20.06 ± 14.58 $0.6-45$ (16.5)Early term23 36.52 ± 77.84 1.383 (16)Term14 56.14 ± 108.93 1.383 (9)Late term7 14.71 ± 9.34 3.25 (19)Postop ASTPreterm10 65.6 ± 56.06 18.180 (39)Early term23 233.48 ± 619.7 12.3041 (104)Term14 362.1 ± 598.2 3.1863 (84)Late term7 217.29 ± 393.43 20.1103 (65)Postop ureaPreterm10 39.9 ± 22.14 9.87 (36)Early term23 49.96 ± 36.4 8.184 (39)Term14 54.93 ± 22.13 26.99 (55.5)Late term7 51.71 ± 25.41 26.85 (43)Postop creatininePreterm10 0.63 ± 0.37 $0.22.1.43$ (0.47)Early term23 1 ± 0.77 $0.16.3.5$ (0.9)Term14 1.23 ± 0.71 $0.34.2.33$ (1.04)Late term7 1.19 ± 0.85 $0.3.2.21$ (1.31)Postop PLTPreterm10 122.3 ± 54.38 54.216 (117)Early term23 205.52 ± 106.79 20.378 (195)					. ,	
Term14 270.71 ± 130.78 $133-625$ (258)Late term7 216 ± 128.47 $57-361$ (230)Postop ALTPreterm10 20.06 ± 14.58 $0.6-45$ (16.5)Early term23 36.52 ± 77.84 $1-383$ (16)Term14 56.14 ± 108.93 $1-383$ (9)Late term7 14.71 ± 9.34 $3-25$ (19)Postop ASTPreterm10 65.6 ± 56.06 $18-180$ (39)Early term23 233.48 ± 619.7 $12-3041$ (104)Term14 3621 ± 598.2 $3-1863$ (84)Late term7 217.29 ± 393.43 $20-1103$ (65)Postop ureaPreterm10 39.9 ± 22.14 $9-87$ (36)Early term23 49.96 ± 36.4 $8-184$ (39)Term14 54.93 ± 22.13 $26-99$ (55.5)Late term7 51.71 ± 25.41 $26-85$ (43)Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43$ (0.47)Early term23 1 ± 0.77 $0.16-3.5$ (0.9)Term14 1.23 ± 0.71 $0.34-2.33$ (1.04)Late term7 1.19 ± 0.85 $0.3-2.21$ (1.31)Postop PLTPreterm10 122.3 ± 54.38 $54-216$ (117)Postop PLTPreterm10 122.3 ± 10.79 $20-378$ (195)	Preop PLT					0.543
Late term7 216 ± 128.47 $57-361$ (230)Postop ALTPreterm10 20.06 ± 14.58 $0.6-45$ (16.5)Early term23 36.52 ± 77.84 $1-383$ (16)Term14 56.14 ± 108.93 $1-383$ (9)Late term7 14.71 ± 9.34 $3-25$ (19)Postop ASTPreterm10 65.6 ± 56.06 $18-180$ (39)Early term23 233.48 ± 619.7 $12-3041$ (104)Term14 369.21 ± 598.2 $3-1863$ (84)Late term7 217.29 ± 393.43 $20-1103$ (65)Postop ureaPreterm10 39.9 ± 22.14 $9-87$ (36)Postop ureaPreterm10 39.9 ± 22.13 $26-99$ (55.5)Late term7 51.71 ± 25.41 $26-85$ (43)Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43$ (0.47)Early term23 1 ± 0.77 $0.16-3.5$ (0.9)Term14 1.23 ± 0.71 $0.34-2.33$ (1.04)Late term7 1.19 ± 0.85 $0.3-2.21$ (1.31)Postop PLTPreterm10 122.3 ± 54.38 $54-216$ (117)Early term23 205.52 ± 106.79 20.378 (195)						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Term	14	270.71 ± 130.78		
Early term23 36.52 ± 77.84 $1.383 (16)$ Term14 56.14 ± 108.93 $1.383 (9)$ Late term7 14.71 ± 9.34 $3.25 (19)$ Postop ASTPreterm10 65.6 ± 56.06 $18.180 (39)$ Early term23 233.48 ± 619.7 $12.3041 (104)$ Term14 369.21 ± 598.2 $3.1863 (84)$ Late term7 217.29 ± 393.43 $20.1103 (65)$ Postop ureaPreterm10 39.9 ± 22.14 $9.87 (36)$ Early term23 49.96 ± 36.4 $8.184 (39)$ Term14 54.93 ± 22.13 $26-99 (55.5)$ Late term7 51.71 ± 25.41 $26-85 (43)$ Postop creatininePreterm10 0.63 ± 0.37 $0.22.1.43 (0.47)$ Early term23 1 ± 0.77 $0.16-3.5 (0.9)$ Term14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20.378 (195)$		Late term	7	216 ± 128.47	57-361 (230)	
Term 14 56.14 ± 108.93 1-383 (9) Late term 7 14.71 ± 9.34 3-25 (19) Postop AST Preterm 10 65.6 ± 56.06 18-180 (39) Early term 23 233.48 ± 619.7 12-3041 (104) Term 14 369.21 ± 598.2 3-1863 (84) Late term 7 217.29 ± 393.43 20-1103 (65) Postop urea Preterm 10 39.9 ± 22.14 9-87 (36) Early term 23 49.96 ± 36.4 8-184 (39) Term 14 54.93 ± 22.13 26-99 (55.5) Late term 7 51.71 ± 25.41 26-85 (43) Postop creatinine Preterm 10 0.63 ± 0.37 0.22-1.43 (0.47) Early term 23 1 ± 0.77 0.16-3.5 (0.9) 1 ± 0.77 Term 14 1.23 ± 0.71 0.34-2.33 (1.04) 1 ± 0.77 Late term 7 1.19 ± 0.85 0.3-2.21 (1.31) Postop PLT Preterm 10 122.3 ± 54.38 54-216 (117) <tr< td=""><td>Postop ALT</td><td>Preterm</td><td>10</td><td>20.06 ± 14.58</td><td>0.6-45 (16.5)</td><td>0.938</td></tr<>	Postop ALT	Preterm	10	20.06 ± 14.58	0.6-45 (16.5)	0.938
Late term7 14.71 ± 9.34 $3-25 (19)$ Postop ASTPreterm10 65.6 ± 56.06 $18-180 (39)$ Early term23 233.48 ± 619.7 $12-3041 (104)$ Term14 369.21 ± 598.2 $3-1863 (84)$ Late term7 217.29 ± 393.43 $20-1103 (65)$ Postop ureaPreterm10 39.9 ± 22.14 $9-87 (36)$ Postop ureaPreterm23 49.96 ± 36.4 $8-184 (39)$ Term14 54.93 ± 22.13 $26-99 (55.5)$ Late term7 51.71 ± 25.41 $26-85 (43)$ Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43 (0.47)$ Postop treatininePreterm14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20-378 (195)$		Early term	23	36.52 ± 77.84	1-383 (16)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Term	14	56.14 ± 108.93	1-383 (9)	
IEarly term23233.48 \pm 619.712-3041 (104)Term14369.21 \pm 598.23-1863 (84)Late term7217.29 \pm 393.4320-1103 (65)Postop ureaPreterm1039.9 \pm 22.149-87 (36)Early term2349.96 \pm 36.48-184 (39)Term1454.93 \pm 22.1326-99 (55.5)Late term751.71 \pm 25.4126-85 (43)Postop creatininePreterm100.63 \pm 0.370.22-1.43 (0.47)Early term231 \pm 0.770.16-3.5 (0.9)Term141.23 \pm 0.710.34-2.33 (1.04)Postop PLTPreterm10122.3 \pm 54.3854-216 (117)Early term23205.52 \pm 106.7920-378 (195)		Late term	7	14.71 ± 9.34	3-25 (19)	
Term14 369.21 ± 598.2 $3-1863$ (84)Late term7 217.29 ± 393.43 $20-1103$ (65)Postop ureaPreterm10 39.9 ± 22.14 $9-87$ (36)Early term23 49.96 ± 36.4 $8-184$ (39)Term14 54.93 ± 22.13 $26-99$ (55.5)Late term7 51.71 ± 25.41 $26-85$ (43)Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43$ (0.47)Early term23 1 ± 0.77 $0.16-3.5$ (0.9)Term14 1.23 ± 0.71 $0.34-2.33$ (1.04)Late term7 1.19 ± 0.85 $0.3-2.21$ (1.31)Postop PLTPreterm10 122.3 ± 54.38 $54-216$ (117)Early term23 205.52 ± 106.79 $20-378$ (195)	Postop AST	Preterm	10	65.6 ± 56.06	18-180 (39)	0.552
Late term7 217.29 ± 393.43 $20-1103$ (65)Postop ureaPreterm10 39.9 ± 22.14 $9-87$ (36)Early term23 49.96 ± 36.4 $8-184$ (39)Term14 54.93 ± 22.13 $26-99$ (55.5)Late term7 51.71 ± 25.41 $26-85$ (43)Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43$ (0.47)Early term23 1 ± 0.77 $0.16-3.5$ (0.9)Term14 1.23 ± 0.71 $0.34-2.33$ (1.04)Late term7 1.19 ± 0.85 $0.3-2.21$ (1.31)Postop PLTPreterm10 122.3 ± 54.38 $54-216$ (117)Early term23 205.52 ± 106.79 $20-378$ (195)		Early term	23	233.48 ± 619.7	12-3041 (104)	
Postop ureaPreterm10 39.9 ± 22.14 $9-87 (36)$ Early term23 49.96 ± 36.4 $8-184 (39)$ Term14 54.93 ± 22.13 $26-99 (55.5)$ Late term7 51.71 ± 25.41 $26-85 (43)$ Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43 (0.47)$ Early term23 1 ± 0.77 $0.16-3.5 (0.9)$ Term14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20-378 (195)$		Term	14	369.21 ± 598.2	3-1863 (84)	
Image: Form of the term23 49.96 ± 36.4 $8-184 (39)$ Term14 54.93 ± 22.13 $26-99 (55.5)$ Late term7 51.71 ± 25.41 $26-85 (43)$ Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43 (0.47)$ Early term23 1 ± 0.77 $0.16-3.5 (0.9)$ Term14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20-378 (195)$		Late term	7	217.29 ± 393.43	20-1103 (65)	
Term14 54.93 ± 22.13 $26-99 (55.5)$ Late term7 51.71 ± 25.41 $26-85 (43)$ Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43 (0.47)$ Early term23 1 ± 0.77 $0.16-3.5 (0.9)$ Term14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20-378 (195)$	Postop urea	Preterm	10	39.9 ± 22.14	9-87 (36)	0.432
Late term7 51.71 ± 25.41 $26-85 (43)$ Postop creatininePreterm10 0.63 ± 0.37 $0.22-1.43 (0.47)$ Early term23 1 ± 0.77 $0.16-3.5 (0.9)$ Term14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20-378 (195)$		Early term	23	49.96 ± 36.4	8-184 (39)	
Postop creatinine Preterm 10 0.63 ± 0.37 $0.22-1.43 (0.47)$ Early term 23 1 ± 0.77 $0.16-3.5 (0.9)$ Term 14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term 7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLT Preterm 10 122.3 ± 54.38 $54-216 (117)$ Early term 23 205.52 ± 106.79 $20-378 (195)$		Term	14	54.93 ± 22.13	26-99 (55.5)	
Early term23 1 ± 0.77 $0.16-3.5 (0.9)$ Term14 1.23 ± 0.71 $0.34-2.33 (1.04)$ Late term7 1.19 ± 0.85 $0.3-2.21 (1.31)$ Postop PLTPreterm10 122.3 ± 54.38 $54-216 (117)$ Early term23 205.52 ± 106.79 $20-378 (195)$		Late term	7	51.71 ± 25.41	26-85 (43)	
Term 14 1.23 ± 0.71 0.34-2.33 (1.04) Late term 7 1.19 ± 0.85 0.3-2.21 (1.31) Postop PLT Preterm 10 122.3 ± 54.38 54-216 (117) Early term 23 205.52 ± 106.79 20-378 (195)	Postop creatinine	Preterm	10	0.63 ± 0.37	0.22-1.43 (0.47)	0.200
Late term 7 1.19 ± 0.85 0.3-2.21 (1.31) Postop PLT Preterm 10 122.3 ± 54.38 54-216 (117) Early term 23 205.52 ± 106.79 20-378 (195)		Early term	23	1 ± 0.77	0.16-3.5 (0.9)	
Postop PLT Preterm 10 122.3 ± 54.38 54-216 (117) Early term 23 205.52 ± 106.79 20-378 (195)		Term	14	1.23 ± 0.71	0.34-2.33 (1.04)	
Early term 23 205.52 ± 106.79 20-378 (195)		Late term	7	1.19 ± 0.85	0.3-2.21 (1.31)	
•	Postop PLT	Preterm			54-216 (117)	0.167
Tarm 14 155 57 + 96 61 46 209 (121 5)		-				
ItemItemItemItemItemItemLate term7 155.43 ± 91.45 $63-270$ (98)		Term	14	155.57 ± 86.61	46-308 (131.5)	

the change between the preoperative and postoperative platelet counts, postoperative saturation levels, bypass times, CC times, the volume of the drained fluid on the first postoperative day, and the length of stay in ICU (p > 0.05).

There is a positive and weakly significant correlation between the bypass time and the change between preoperative and postoperative platelet counts (r=0.400, p<0.01). There is not a statistically significant relationship of the change in platelet counts with PDA diameters, postoperative saturation levels, CC times, postoperative VIS scores, drained fluid volumes on the first postoperative day, and the length of ICU stay (p>0.05).

There is not a statistically significant relationship of PDA diameters with postoperative saturation levels, bypass times, CC times, postoperative VIS scores, drained fluid volumes on the first postoperative day, and the length of stay in ICU (p> 0.05).

There is a positive and moderately significant correlation between the bypass time and the CC time (r= 0.565, p< 0.01). There is a positive and weakly significant relationship between the bypass time and postoperative VIS scores (r= 0.317, p< 0.05). There is not a statistically significant relationship of the bypass time with the volume of the drained fluid on the first postoperative day and the length of ICU stay (p> 0.05).

There is a negative and weakly significant relationship between the CC time and the length of ICU stay (r=-0.297, p<0.05).

There is a negative and weakly significant relationship between postoperative VIS scores and the length of ICU stay (r= -0.278, p< 0.05). There is not a statistically significant relationship between postoperative VIS scores and the volume of the drained fluid on the first postoperative day (p> 0.05).

There is a positive and weakly significant relationship between the volume of the drained fluid on the first postoperative day and the length of ICU stay (r=0.312, p<0.05).

Preoperative levels of ALT, AST, urea, creatinine, and preoperative platelet counts did not show any statistically significant differences by term pregnancies (p > 0.05). Postoperative levels of ALT, AST, urea, creatinine, and preoperative platelet counts did not show any statistically significant differences by term pregnancies (p > 0.05) (Table 6).

DISCUSSION

Although mortality rates associated with the Norwood operation continue to decrease upon the introduction of many technical and technological advances in pediatric cardiac surgery in the last 20 years, mortality and morbidity of the procedure are still high in the early postoperative period. The following anomalies accompanying HLHS; including pulmonary venous return anomaly, advanced atrioventricular valve insufficiency, low birthweight, low gestational age, diagnosed or suspected genetic anomalies, and the presence of a restrictive or intact atrial septum are the most important risk factors for Norwood operation in the early postoperative period⁽¹⁴⁻¹⁶⁾.

Higher gestational age, higher birth weight, advanced organ maturation, and completion of fetal development increase the likelihood of successful surgical outcomes after such a difficult operation. As for the maturation of lungs; formation of airways, development of the lung parenchyma, and formation of capillaries occur in the intrauterine period until the 36th gestational week. Pathogens settle more easily in immature bronchial walls of babies born in earlier gestational weeks, leaving the baby more vulnerable to respiratory infections⁽¹⁷⁻¹⁹⁾. Our results correlate with the results reported by previous studies showing that the development of bronchopulmonary dysplasia in infants born in early gestational weeks cause lower postoperative saturation levels and a higher need for mechanical ventilation compared to infants born in later gestational weeks.

In our study, we have found that patients born in early gestational weeks with low birth weight are associated with high risks. We have found that mortality and morbidity decreased significantly in patients born at gestational ages of 272 days (38.8 weeks) and later. Furthermore, we have found that the increase in bypass and CC times during the operation extended the stay in ICU.

In the study conducted by Baba et al., mortality and morbidity of the Norwood stage 1 operation were not statistically significantly different compared to those of the hybrid procedure; which was used as an alternative to the Norwood stage 1 operation in some centers. Postoperative prognosis in single ventricle patients is more likely related to patient-associated preoperative risk factors compared to the surgical technique used for intervention^(20,21). In the study conducted by Mascio et al., it was shown that; considering the gradual decline in mortality over the last 15 years, prognosis continued to depend on patient-associated preoperative risk factors more than the use of advanced surgical techniques and a hybrid approach. That study showed that postoperative mortality increased proportionally to the increase in the number of patient-specific risk factors (3 or more accompanying risk factors)(22). In our retrospective cohort study, we found that postoperative mortality was higher when the gestational age was 38.8 weeks and lower.

It is difficult to adjust the balance of pulmonary and systemic blood flow in patients born at an earlier gestational age with low birth weight. When 3.5 mm diameter modified Blalock-Taussig shunt grafts are used in such patients, the pulmonary shunt causes pulmonary blood flow to increase extensively resulting in overflow. However, 3 mm grafts cause thrombosis and technical difficulties⁽²³⁾. In our patient group, we mostly used 5 mm pulmonary shunt grafts extending from the right ventricle to the pulmonary artery. We used 3.5 mm modified Blalock-Taussig shunt grafts in only fourteen patients.

Risk factors are not limited to premature birth and low birth weight in HLHS patients. Need for extracorporeal membrane oxygenation (ECMO) after the Norwood operation, postoperative need for emergency surgery, preoperative organ dysfunctions, and infections are the factors acting on prognosis. The Norwood operation should be scheduled as soon as possible in single ventricle patients because it is not a pathology compatible with life. The single ventricle anomaly does not allow the patient to gain weight and mature after birth. Therefore; the higher the gestational age, the more chances the patient will have⁽²²⁻²⁴⁾. In our study: despite the lack of significant differences in the change between preoperative and postoperative values of ALT, AST, creatinine, and platelets by term pregnancies, these parameters were found to be correlated with the gestational week. This finding probably results from the difference in patient distribution patterns across the groups in the study.

Familial genes and environmental factors act significantly on postoperative outcomes across similar gestational ages because; despite similarities, intrauterine development varies from one infant to another depending on genetic factors⁽²⁵⁻²⁷⁾. Furthermore; infections due to postoperative ECMO, open sternum, surgical resection of the thymus, and immaturity of the immune system in the newborn act on mortality and morbidity⁽²⁸⁻³⁰⁾. Although we have not found a correlation between the postoperative need for inotropes (VIS scores) and the gestational week in our study, we think that this finding resulted from the combination of more than one factor including bypass and CC times, genetic characteristics of patients, birth weight, preoperative cardiac conditions, and infections.

LIMITATIONS

This cohort has a heterogeneous data distribution pattern obtained from 54 patients, who underwent stage 1 Norwood operation. The gestational age and other patient data were retrieved from patients' medical files retrospectively. Many factors act on the prognosis after the Norwood operation. The gestational week is just one of these parameters. Because prognosis may be affected by other factors such as infection and ECMO support, further large-scale studies are needed.

CONCLUSION

In conclusion, preoperative risk factors act on prognosis more strongly than the surgical technique and the treatment approach in patients with a functional single ventricle. In our study; the gestational week, as a preoperative risk factor, was found to be actively acting on the postoperative prognosis of stage 1 Norwood operation as mortality declined significantly after the 38.8th gestational week (272 gestational days). Ethics Committee Approval: The study protocol was approved by the local ethics committee. The study was conducted in accordance with the principles of the Declaration of Helsinki (2021/4/457).

Informed Consent: Informed consent was obtained.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept/Design - EA; Analysis/Interpretation - KK; Data Collection - AH; Writing - EA, KK; Critical Revision - BT; Final Approval - HC; Statistical Analysis - FI, ET; Obtained funding - ÖŞ; Overall Responsibility - NÇ, HC.

Conflict of Interest: The authors have no conflicts of interest to declare

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

- Lev M. Pathologic anatomy and interrelationship of hypoplasia of the aortic tract complexes. Lab Invest 1952;1:61-70.
- Noonan JA, Nadas AS. The hypoplastic left heart syndrome; an analysis of 101 cases. Pediatr Clin North Am 1958;5:1029-56.
- Doty DB, Knott HW. Hypoplastic left heart syndrome. Experience with an operation to establish functionally normal circulation. J Thorac Cardiovasc Surg 1977;74:624-30.
- Norwood WI, Lang P, Hansen DD. Physiologic repair of aortic atresiahypoplastic left heart syndrome. N Engl J Med 1983;308:23-6.
- Malik S, Cleves MA, Zhao W, Correa A, Hobbs CA. Association between congenital heart defects and small for gestational age. Pediatrics 2007;119:e976-e982.
- Rosenthal GL. Patterns of prenatal growth among infants with cardiovascular malformations: possible fetal hemodynamic effects. Am J Epidemiol 1996;143:505-13.
- Rosenthal GL, Wilson PD, Permutt T, Boughman JA, Ferencz C. Birth weight and cardiovascular malformations: a population-based study. The Baltimore-Washington Infant Study. Am J Epidemiol 1991;133:1273-81.
- Tanner K, Sabrine N, Wren C. Cardiovascular malformations among preterm infants. Pediatrics 2005;116:e833-e838.
- Grantham-McGregor SM. Small for gestational age, term babies, in the first six years of life. Eur J Clin Nutr 1998;52(Suppl 1):S59-S64.
- Morley R, Fewtrell MS, Abbott RA, Stephenson T, MacFadyen U, Lucas A. Neurodevelopment in children born small for gestational age: a randomized trial of nutrient-enriched versus standard formula and comparison with a reference breastfed group. Pediatrics 2004;113:515-21.
- Curzon CL, Milford-Beland S, Li JS, O'Brien SM, Jacobs JP, Jacobs ML, et al. Cardiac surgery in infants with low birth weight is associated with increased mortality: analysis of the Society of Thoracic Surgeons Congenital Heart Database. J Thorac Cardiovasc Surg 2008;135:546-51.
- Oppido G, Napoleone CP, Formigari R, Gabbieri D, Pacini D, Frascaroli FG, et al. Outcome of cardiac surgery in low birth weight and premature infants. Eur J Cardiothorac Surg 2004;26:44-53.
- Ghanayem NS, Hoffman GM, Mussatto KA, Frommelt MA, Cava JR, Mitchell ME, et al. Perioperative monitoring in high-risk infants after stage 1 palliation of univentricular congenital heart disease. J Thorac Cardiovasc Surg 2010;140:857-63.
- Costello JM, Pasquali SK, Jacobs JP, He X, Hill KD, Cooper DS, et al. Gestational age at birth and outcomes after neonatal cardiac surgery: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database. Circulation 2014;129:2511-7.

- O'Reilly M, Sozo F, Harding R. Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health. Clin Exp Pharmacol Physiol 2013;40:765-73.
- McMahon CJ, Penny DJ, Nelson DP, Ades AM, Maskary SA, Speer M, et al. Preterm infants with congenital heart disease and bronchopulmonary dysplasia: postoperative course and outcome after cardiac surgery. Pediatrics 2005;116:423-30.
- Hickey EJ, Nosikova Y, Zhang H, Caldarone CA, Benson L, Redington A, et al. Very low-birth-weight infants with congenital cardiac lesions: is there merit in delaying intervention to permit growth and maturation? J Thorac Cardiovasc Surg 2012;143:126-36.
- Sahni R, Polin RA. Physiologic underpinnings for clinical problems in moderately preterm and late preterm infants. Clin Perinatol 2013;40:645-63.
- Alsoufi B, Gillespie S, Kogon B, Schlosser B, Sachdeva R, Kim D, et al. Results of palliation with an initial modified Blalock Taussig shunt in neonates with single ventricle anomalies associated with restrictive pulmonary blood flow. Ann Thorac Surg 2015;99:1639-46.
- Baba K, Kotani Y, Chetan D, Chaturvedi RR, Lee KJ, Benson NL, et al. Hybrid versus Norwood strategies for single-ventricle palliation. Circulation 2012;126(11 Suppl 1):S123-31.
- Mascio CE, Irons ML, Ittenbach RF, Gaynor JW, Fuller SM, Kaplinski M, et al. Thirty years and 1663 consecutive Norwood procedures: Has survival plateaued? J Thorac Cardiovasc Surg 2019;158:220-9.
- Sano S, Huang SC, Kasahara S, Yoshizumi K, Kotani Y, Ishino K. Risk factors for mortality after the Norwood procedure using right ventricle to pulmonary artery shunt. Ann Thorac Surg 2009;87:178-85; discussion 185-6.

- Wilder TJ, McCrindle BW, Hickey EJ, Ziemer G, Tchervenkov CI, Jacobs ML, et al. Is a hybrid strategy a lower-risk alternative to stage 1 Norwood operation? J Thorac Cardiovasc Surg 2017;153:163-72.e6.
- Oppido G, Napoleone CP, Formigari R, Gabbieri D, Pacini D, Frascaroli G, et al. Outcome of cardiac surgery in low birth weight and premature infants. Eur J Cardiothorac Surg 2004;26:44-53.
- Kussman BD, Gauvreau K, DiNardo JA, Newburger JW, Mackie AS, Booth KL, et al. Cerebral perfusion and oxygenation after the Norwood procedure: comparison of right ventricle-pulmonary artery conduit with modified Blalock-Taussig shunt. J Thorac Cardiovasc Surg 2007;133:648-55.
- Yıldırım Ö, Bakhshaliyev S, Kilercik H, Balaban İ, Zübarioğlu U, Konukoğlu O, et al. Early results of ring-reinforced conduit and curved porcine patch in Sano-Norwood procedure. J Card Surg 2019;34:279-84.
- Bove T, Francois K, De Groote K, Suys B, De Wolf D, Verhaaren H, et al. Outcome analysis of major cardiac operations in low weight neonates. Ann Thorac Surg 2004;78:181-7.
- Rollins CK, Newburger JW, Roberts AE. Genetic contribution to neurodevelopmental outcomes in congenital heart disease: are some patients predetermined to have developmental delay? Curr Opin Pediatr 2017;29:529-33.
- Russell MW, Chung WK, Kaltman JR, Miller TA. Advances in the understanding of the genetic determinants of congenital heart disease and their impact on clinical outcomes. J Am Heart Assoc 2018;7:e006906.
- Prior T, Wild M, Mullins E, Bennett P, Kumar S. Sex specific differences in fetal middle cerebral artery and umbilical venous Doppler. PLoS One 2013;8(2):e56933.